Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 29.04
CSII's Cash to Debt is ranked higher than
71% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. CSII: 29.04 )
CSII' s 10-Year Cash to Debt Range
Min: 1.11   Max: No Debt
Current: 29.04

Equity to Asset 0.86
CSII's Equity to Asset is ranked higher than
91% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. CSII: 0.86 )
CSII' s 10-Year Equity to Asset Range
Min: -1.4   Max: 0.94
Current: 0.86

-1.4
0.94
F-Score: 4
Z-Score: 18.58
M-Score: -2.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -21.58
CSII's Operating margin (%) is ranked higher than
50% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. CSII: -21.58 )
CSII' s 10-Year Operating margin (%) Range
Min: -7725.17   Max: 3.82
Current: -21.58

-7725.17
3.82
Net-margin (%) -23.14
CSII's Net-margin (%) is ranked higher than
51% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. CSII: -23.14 )
CSII' s 10-Year Net-margin (%) Range
Min: -7634.69   Max: 13.13
Current: -23.14

-7634.69
13.13
ROE (%) -35.97
CSII's ROE (%) is ranked lower than
52% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. CSII: -35.97 )
CSII' s 10-Year ROE (%) Range
Min: -134.94   Max: 9.33
Current: -35.97

-134.94
9.33
ROA (%) -24.81
CSII's ROA (%) is ranked lower than
51% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. CSII: -24.81 )
CSII' s 10-Year ROA (%) Range
Min: -87.8   Max: 8.12
Current: -24.81

-87.8
8.12
ROC (Joel Greenblatt) (%) -294.48
CSII's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. CSII: -294.48 )
CSII' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1088.14   Max: 117.48
Current: -294.48

-1088.14
117.48
Revenue Growth (%) 2.90
CSII's Revenue Growth (%) is ranked higher than
67% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. CSII: 2.90 )
CSII' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 23.9
Current: 2.9

0
23.9
EBITDA Growth (%) -12.80
CSII's EBITDA Growth (%) is ranked higher than
66% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. CSII: -12.80 )
CSII' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 79.4
Current: -12.8

0
79.4
EPS Growth (%) -11.80
CSII's EPS Growth (%) is ranked higher than
66% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. CSII: -11.80 )
CSII' s 10-Year EPS Growth (%) Range
Min: -66.2   Max: 81.2
Current: -11.8

-66.2
81.2
» CSII's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

CSII Guru Trades in Q4 2012

Jim Simons 35,300 sh (+85.79%)
» More
Q1 2013

CSII Guru Trades in Q1 2013

Steven Cohen 14,935 sh (New)
Jim Simons 62,800 sh (+77.9%)
» More
Q2 2013

CSII Guru Trades in Q2 2013

Steven Cohen Sold Out
Jim Simons Sold Out
» More
Q4 2013

CSII Guru Trades in Q4 2013

Jim Simons 94,600 sh (New)
Paul Tudor Jones 6,792 sh (New)
Steven Cohen 169,931 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CSII

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Lee Ainslie 2012-03-31 Sold Out 0.01%$8.6 - $10.45 $ 26.08198%0
Lee Ainslie 2011-12-31 Reduce -62.32%0.02%$7.41 - $10.3 $ 26.08187%60947
Lee Ainslie 2011-09-30 New Buy0.03%$11.57 - $16.1 $ 26.0889%161747
Lee Ainslie 2011-06-30 Sold Out 0.16%$10.59 - $15.43 $ 26.08104%0
George Soros 2011-06-30 Sold Out $10.59 - $15.43 $ 26.08104%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.80
CSII's P/B is ranked lower than
59% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. CSII: 4.80 )
CSII' s 10-Year P/B Range
Min: 0.12   Max: 14.53
Current: 4.8

0.12
14.53
P/S 5.40
CSII's P/S is ranked lower than
69% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. CSII: 5.40 )
CSII' s 10-Year P/S Range
Min: 0.19   Max: 7.61
Current: 5.4

0.19
7.61
EV-to-EBIT 5.20
CSII's EV-to-EBIT is ranked higher than
95% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. CSII: 5.20 )
CSII' s 10-Year EV-to-EBIT Range
Min: 0.4   Max: 4.9
Current: 5.2

0.4
4.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.10
CSII's Price/Net Cash is ranked higher than
73% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 14.30 vs. CSII: 6.10 )
CSII' s 10-Year Price/Net Cash Range
Min: 0.54   Max: 231.2
Current: 6.1

0.54
231.2
Price/Net Current Asset Value 5.40
CSII's Price/Net Current Asset Value is ranked higher than
73% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. CSII: 5.40 )
CSII' s 10-Year Price/Net Current Asset Value Range
Min: 0.54   Max: 41.65
Current: 5.4

0.54
41.65
Price/Tangible Book 4.90
CSII's Price/Tangible Book is ranked higher than
51% of the 328 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. CSII: 4.90 )
CSII' s 10-Year Price/Tangible Book Range
Min: 0.52   Max: 12.77
Current: 4.9

0.52
12.77
Price/Median PS Value 2.60
CSII's Price/Median PS Value is ranked lower than
73% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. CSII: 2.60 )
CSII' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 3.45
Current: 2.6

0.3
3.45
Earnings Yield (Greenblatt) 19.40
CSII's Earnings Yield (Greenblatt) is ranked higher than
95% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. CSII: 19.40 )
CSII' s 10-Year Earnings Yield (Greenblatt) Range
Min: 18.9   Max: 258.9
Current: 19.4

18.9
258.9
Forward Rate of Return (Yacktman) -48.20
CSII's Forward Rate of Return (Yacktman) is ranked higher than
51% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. CSII: -48.20 )
CSII' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 41.8   Max: 4506.5
Current: -48.2

41.8
4506.5

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:R7Y1.Germany
Cardiovascular Systems, Inc. was incorporated as Replidyne, Inc. in Delaware in 2000. On February 25, 2009, Replidyne, Inc. completed its business combination with Cardiovascular Systems, Inc., a Minnesota Corporation. At the effective time of the merger, Replidyne changed its name to Cardiovascular Systems, Inc. CSI is a medical device company focused on developing and commercializing minimally invasive treatment solutions for vascular disease. Interventional endovascular treatment of peripheral artery disease, or PAD, was the initial area of focus. PAD is caused by the accumulation of plaque in peripheral arteries, most commonly occurring in the pelvis and legs, and affects approximately eight to 12 million people in the United States. Its initial product, the Diamondback 360(r) PAD System, is a catheter-based platform capable of treating a range of plaque types in leg arteries both above and below the knee and addresses many of the limitations associated with existing treatment alternatives. The Diamondback 360°'s single-use catheter incorporates a flexible drive shaft with an offset crown coated with diamond grit. With the aid of fluoroscopy, the physician positions the crown at a plaque-containing lesion in the peripheral artery and removes the plaque by causing the crown to orbit against it. This mechanism of action creates a smooth lumen, or channel, in the vessel. The Diamondback 360° is designed to differentiate between plaque and compliant arterial tissue, a concept known as 'differential sanding'. The Diamondback 360° sands plaque into small particles and restores both blood flow and vessel compliance. The particles created by the Diamondback 360° are generally smaller than red blood cells and are carried away by the bloodstream. The small size of the particles avoids the need for plaque collection reservoirs. The Diamondback 360° could treat the diseased arteries with less than three minutes of sanding time, potentially reducing the overall procedure time. In addition to the Diamondback 360°, the Company is expanding its product portfolio through internal product development and establishment of business relationships. CSI now offers multiple accessory devices designed to complement the use of the Diamondback 360°, and have entered into distribution agreements with Invatec, Inc. and Asahi-Intecc, Ltd. CSI markets and sells the Diamondback 360° through a direct sales force in the United States. The Company target its marketing efforts to practitioners through physician education, medical conferences, seminars, peer reviewed journals and marketing materials. The medical device industry is highly competitive, subject to rapid change and is affected by new product introductions and other activities of industry participants. The competitors in the stent and balloon angioplasty market segments include Abbott Laboratories, Boston Scientific, Cook, Johnson & Johnson and Medtronic. The Company also compete against manu

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide